BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38030205)

  • 1. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
    Kobayashi A; Ikemura K; Wakai E; Kondo M; Okuda M
    Anticancer Res; 2023 Dec; 43(12):5613-5620. PubMed ID: 38030205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.
    Yokoyama S; Nakagawa C; Hosomi K
    Support Care Cancer; 2022 Feb; 30(2):1765-1773. PubMed ID: 34595605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of the Effect of Proton Pump Inhibitors on the Anticancer Activity of Oxaliplatin.
    Hashizume J; Sato K; Nakagawa H; Harasawa H; Honda T; Kodama Y
    Cancer Diagn Progn; 2022; 2(6):620-626. PubMed ID: 36340458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.
    Teng C; Cohen J; Egger S; Blinman PL; Vardy JL
    Support Care Cancer; 2022 Jan; 30(1):33-47. PubMed ID: 34410459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial.
    Chan K; Lui L; Lam Y; Yu K; Lau K; Lai M; Lau W; Tai L; Mak C; Bian Z; Zhong LL
    Acupunct Med; 2023 Oct; 41(5):268-283. PubMed ID: 36325677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database.
    Mine K; Kawashiri T; Inoue M; Kobayashi D; Mori K; Hiromoto S; Kudamatsu H; Uchida M; Egashira N; Koyanagi S; Ohdo S; Shimazoe T
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
    Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
    BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database.
    Inoue M; Matsumoto K; Tanaka M; Yoshida Y; Satake R; Goto F; Shimada K; Mukai R; Hasegawa S; Suzuki T; Ikesue H; Liao J; Hashida T; Nakamura M
    Sci Rep; 2021 May; 11(1):11324. PubMed ID: 34059747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats.
    Nishida K; Takeuchi K; Hosoda A; Sugano S; Morisaki E; Ohishi A; Nagasawa K
    Life Sci; 2018 Aug; 207():516-524. PubMed ID: 29981320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy.
    Wang CY; Lin TT; Hu L; Xu CJ; Hu F; Wan L; Yang X; Wu XF; Zhang XT; Li Y; Yin HY; Jiang CY; Xin HL; Liu WT
    EBioMedicine; 2023 Apr; 90():104499. PubMed ID: 36870200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.